drugset

drugset / Trial / NCT03033368

Rilpivirine in Virologically Suppressed Adolescents

NCT03033368 ↗

Phase 2/3 Unknown 100 enrolled Mahidol University amfAR, The Foundation for AIDS Research · collab

NaSingle-groupOpen-labelTreatment

Summary

To describe the immunologic and virologic outcomes (HIV RNA, CD4) following switching from EFV to RPV in virologically suppressed adolescents

Timeline

Start: 2015-07
Primary completion: 2017-06
Completion: 2017-12

Publications

Jantarabenjakul W, Anugulruengkitt S, Kasipong N, Thammajaruk N, Sophonphan J, Bunupuradah T, Cressey TR, Colbers A, Burger DM, Phongsamart W, Puthanakit T, Pancharoen C; HIVNAT 220 study. Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents. Antivir Ther. 2018;23(3):259-265. doi: 10.3851/IMP3198.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rilpivirine	Small molecule	25 mg	—

Indications